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Introduction
Owing to their crucial role in the modulation of cell pathways, 
protein kinases are important targets for anticancer drug 
discovery.1 The classic approach of targeting the ATP binding 
site has recently come up against selectivity issues, which can 
be considerably reduced by following an allosteric modulation 
approach. As a matter of fact, novel approaches that target “truly” 
allosteric sites (i.e., distinct from the ATP site) are currently 
gaining a foothold in protein kinase drug discovery. Allosteric 
modulators bind to sites that are less conserved across the kinome 
and only accessible upon conformational changes; therefore, they 
are thought to provide higher selectivity and extended drug target 
residence times.2 Of these, type III inhibitors bind exclusively to 
allosteric pockets located in the proximity of the αC helix, which 
is a central mediator of allosteric activation/inactivation.3 This 
helix is located in the N-lobe beside the active site and is usually 
swung outwards when the kinase is in an inactive conformation.4 
Being closely related to protein kinase inactivation, allosteric 
targeting via displacement of the conserved structural αC helix 
allows a direct and specific modulation mechanism. Allosteric 
modulation mechanisms involving this helix have been 
structurally elucidated in a variety of protein kinases, such as 
MEKs, PDK1, PKCζ, AKT1, and more recently CDK2.3,5,6
CDKs have been intensively investigated as anticancer 
targets, but none of the ATP-competitive CDKs inhibitors have 
yet been approved for clinical use, mainly because of selectivity 
issues.7 In fact, the majority of the inhibitors tested so far were 
able to inhibit several CDKs with comparable IC
50
, but due 
to undesired toxicity, their use at effective doses was limited. 
Nevertheless, the relatively more selective (albeit not as selective 
as an allosteric inhibitor would be) CDK4/CDK6 inhibitor 
PD-0332991 was recently reported to triple the progression-free 
survival in combination with an aromatase inhibitor in patients 
with estrogen receptor-positive breast cancer, further supporting 
the notion that higher selectivity in CDK inhibitors may lead 
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Allosteric targeting of protein kinases via displacement of the structural αC helix with type III allosteric inhibitors is 
currently gaining a foothold in drug discovery. Recently, the first crystal structure of CDK2 with an open allosteric pocket 
adjacent to the αC helix has been described, prospecting new opportunities to design more selective inhibitors, but the 
structure has not yet been exploited for the structure-based design of type III allosteric inhibitors. In this work we report the 
results of a virtual screening campaign that resulted in the discovery of the first-in-class type III allosteric ligands of CDK2. 
Using a combination of docking and post-docking analyses made with our tool BeAR, 7 allosteric ligands (hit rate of 20%) 
with micromolar affinity for CDK2 were identified, some of them inhibiting the growth of breast cancer cell lines in the 
micromolar range. Competition experiments performed in the presence of the Atp-competitive inhibitor staurosporine 
confirmed that the 7 ligands are truly allosteric, in agreement with their design. of these, compound 2 bound CDK2 with 
an eC50 value of 3 μM and inhibited the proliferation of MDA-MB231 and ZR-75–1 breast cancer cells with IC50 values of 
approximately 20 μM, while compound 4 had an eC50 value of 71 μM and IC50 values around 4 μM. Remarkably, the most 
potent compound 4 was able to selectively inhibit CDK2-mediated Retinoblastoma phosphorylation, confirming that its 
mechanism of action is fully compatible with a selective inhibition of CDK2 phosphorylation in cells. Finally, hit expansion 
through analog search of the most potent inhibitor 4 revealed an additional ligand 4g with similar in vitro potency on 
breast cancer cells.
©
20
14
 L
an
de
s 
B
io
sc
ie
nc
e.
 D
o 
no
t d
is
tri
bu
te
.
www.landesbioscience.com Cell Cycle 2297
to clinically relevant candidates.8 Moreover, it was reported that 
CDK isoform- and substrate-selective inhibition can be achieved 
through the use of cyclin groove inhibitors, E2F peptides, 
and other molecules that block recruitment of phosphorylated 
retinoblastoma and/or E2F.9-12
CDK2 is an important member of the CDK family, which 
plays an important role in controlling the G
1
-to-S-phase 
checkpoint and in DNA replication13 and, therefore, represents 
an important pharmacological target for arresting or recovering 
control of the cell cycle in dividing cells.7,14 In CDK2, the αC helix 
is involved in Cyclin recruiting to form an active CDK2/Cyclin 
complex. By inducing or stabilizing an outward orientation of 
the αC helix with an allosteric ligand, the CDK–Cyclin interface 
would be disrupted and kinase activation would be impaired.3 
Recently, crystal structures of CDK2 bound with the extrinsic 
fluorophore 8-anilino-1-naphtalene sulfonate (ANS) have been 
reported.15,16 In the crystals, 2 molecules of ANS bind a cavity 
formed by αC and the nearby strands β4 and β5 and induce 
a remarkable outward displacement of the αC helix, ultimately 
resulting in disruption of the recognition and binding site of 
Cyclin A. Ternary crystal structures of CDK2 in complex with 
ANS and type I inhibitors (JWS648, SU9516, and staurosporine) 
confirmed the truly allosteric nature of this fluorophore and 
resulted in CDK2 conformations nearly identical to that of the 
binary CDK2–ANS complex.15,16 This is the first time that a 
completely allosteric ligand proved to be able to displace the αC 
helix and to inactivate a CDK kinase via an allosteric mechanism, 
prospecting a new strategy to design inhibitors with potentially 
improved selectivity. However, ANS is readily displaced from 
CDK2 upon Cyclin binding, because its affinity for CDK2 (K
d
 = 
37 μM) is significantly lower than that of Cyclin A.15 Therefore, 
the design of compounds able to bind this newly discovered 
allosteric pocket with higher affinity and with better drug-like 
properties is highly desirable.
In this work we have performed a virtual screening of 
commercially available compounds (Asinex collection, ~600 000 
compounds) in the allosteric pocket of the CDK2–ANS binary 
complex. The screening was conducted by using a combination 
of docking (AutoDock 4)17 and our in-house post-docking tool 
BEAR (Binding Estimation After Refinement).18,19
Of the 35 best-ranking compounds tested experimentally, 
7 were able to bind CDK2 in the micromolar range and with 
the expected allosteric mechanism. In fact, these molecules 
bind to the allosteric site with a dose-dependent response, and 
competition experiments performed in the presence of the 
type I inhibitor staurosporine excluded the possibility that the 
identified compounds could be ATP-competitive inhibitors, 
thus confirming their allosteric nature. Some of them proved to 
be able to inhibit the growth of breast cancer cell lines in the 
micromolar range, and the most potent compound of our set 
(compound 4) was able to selectively inhibit CDK2-mediated 
Rb phosphorylation in cells, thus supporting its mechanism 
of action. Finally, hit expansion of compound 4 provided an 
additional active candidate with similar in vitro activity.
Results and Discussion
Using the crystal structure of CDK2 in complex with the 
allosteric probe ANS15 (PDB code 1PXF), a virtual screening 
of commercially available compounds (the Asinex collection, 
>600 000 compounds) in this newly discovered allosteric pocket 
was performed using a combination of docking (AutoDock 
4) and post-docking (BEAR)18,19 methods. BEAR has been 
extensively validated and used in prospective and retrospective 
drug discovery applications. By integrating the structural 
refinement of the docked poses with molecular dynamics and 
a more accurate ranking of potential ligands with MM-PBSA, 
BEAR proved to be able to significantly enrich ranked lists with 
biologically active compounds18–20 and to discover active hits in 
previous virtual screening campaigns.21
Before database screening, the docking protocol was tested for 
its ability to reproduce the crystallographic orientation of ANS. 
Re-docking of ANS retrieved a binding mode that was almost 
identical to that of the co-crystallized ligand (RMSD of 0.529 
Å). Of the 2 ANS molecules bound to the crystal, AutoDock 
placed the ligand in the inner (residue 305.A in 3PXF, named 
ANS1) and conceivably more favorable binding site, with a score 
of −7.4 kcal/mol. According to BEAR, the predicted binding free 
energies (calculated without the inclusion of the entropic term) 
of ANS in the inner (ANS1) and outer (ANS2) pockets were 
−37.7 and −24.6 kcal/mol, respectively, confirming that the inner 
pocket provides higher binding, at least with this ligand.
The selection of compounds for biological evaluation was made 
from the hundred top-scoring compounds ranked according to 
the MM-PBSA scoring function implemented in BEAR. In the 
top hundred compounds, MM-PBSA scores ranged from −59.1 to 
−47.1 kcal/mol. A common feature to all top-scoring compounds 
was a strong ionic interaction with Lys33, i.e., the catalytic lysine 
of CDK2 that lines one side of the inner ANS1 pocket. Moreover, 
all compounds occupied the ANS1 pocket with a combination 
of complementary electrostatic (Lys33) and hydrophobic (Leu55, 
Phe146, Tyr15, Phe80, Leu78, Leu148, Leu66) interactions, 
many of them extending, in all or in part, to the outer ANS2 
pocket, thus creating additional favorable contacts. In the outer 
pocket, a number of top-scoring compounds formed additional 
electrostatic interactions with Lys56 (αC helix) and His71 (β4 
sheet), and hydrophobic interactions with Ile52, Leu76, Leu78, 
Leu37, Val69, and Ile35. To promote the selection of structurally 
diverse compounds, potential hits were grouped into chemical 
classes on the basis of Tanimoto similarity indexes and clustering 
analyses. Then, compound selection was performed by: (1) 
selecting at least one representative of each cluster of compounds; 
(2) the visual inspection of the binding modes; (3) the analysis of 
chemical groups interacting with Lys33. A total of 35 compounds 
were finally purchased and submitted to biological assays.
Compounds were initially screened for their ability to 
bind CDK2 and displace ANS from the allosteric pocket. 
Intrinsically fluorescent compounds were not considered for 
further characterization. Competition experiments showed that 
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7 compounds (compounds 1–7; Chart 1) had a concentration-
dependent ability to displace ANS from CDK2, with EC
50
 values 
in the micromolar range. Selected computational and biological 
properties of these compounds are reported in Table 1. Four of 
the 7 hits have significantly diverse structures (having average 
pairwise Tanimoto similarity coefficients of around 0.2) and 
have been classified as representatives of carbonyl, nitro, and 
carboxylic acid classes of compounds depending on the chemical 
group interacting with Lys33. ADMET predictions performed 
with QikProp (Schrödinger Suite 2011) showed that almost all 
the predicted properties of these compounds fall within the 95% 
range of similar values for known drugs. Therefore, the identified 
compounds may constitute valuable starting points for further 
hit-to-lead optimization.
Figure 1A shows the dose-response curves obtained from 3 
independent experiments. All the compounds showed a typical 
displacement curve. EC
50
 values obtained from these curves 
range from 3 μM for compound 2 to 71 μM for compound 4. 
Chart 1. Chemical structures of the allosteric inhibitors 1–7 and those resulting from the hit expansion of compound 4.
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Compounds 1 (EC
50
 of 7 μM) and 2 (EC
50
 of 3 μM) bound 
CDK2 with an affinity higher than ANS (K
d
 = 37 μM),15 while 
compounds 3 and 5–7 had similar affinity. To confirm the 
truly allosteric nature of these ligands, competition experiments 
between compounds 1–7 and ANS were repeated in the presence 
of a potent ATP-competitive type I inhibitor that blocks the 
ATP site, i.e., staurosporine (Fig. S1 reported as supplementary 
information). The presence of staurosporine did not significantly 
modify the ANS displacement curves of the 7 compounds, 
indicating that the latter compounds do not occupy the ATP site. 
Rather, they compete with ANS for the allosteric site previously 
described by crystallography of the CDK2–ANS complex.15
When tested for their ability to inhibit the CDK2/Cyclin A 
kinase activity, all the 7 hits did not show significant inhibitory 
activity (data not shown) at concentrations showing ANS 
displacement. Ligands were also tested at higher concentrations 
(up to 100 μM), depending on compound solubility. Moreover, 
pre-incubation of CDK2/Cyclin A with compounds 1–7 for 
1 h did not show inhibition. Likewise, ANS did not inhibit 
CDK2/Cyclin A activity up to a concentration of 200 μM. In 
the same experimental conditions, the ATP-competitive inhibitor 
staurosporine showed a clear concentration-dependent ability 
to inhibit CDK2/Cyclin A kinase activity, with an IC
50
 of 10 
nM. In the experimental conditions described above, the lack of 
direct inhibition of the catalytic activity shown by compounds 
Table 1. predicted free energies of binding, VS rankings, chemical clas-
sification, occupation of the ANS1 and ANS2 pockets, selected physico–chemical properties, and biological properties of the 7 allosteric inhibitors discov-
ered in the primary virtual screening (compounds 1-7) and of the nine analogs of compound 4 selected from hit expansion (compounds 4a-4i)
Cpd # Asinex # ΔG’bind
a Rank #b Classc ANS1d ANS2d MWe PSAf
logPg 
oct/w
EC50 
(μM)h
IC50 (μM)
i 
MDA-MB231
IC50 (μM)
i ZR-75–1
1 BAS01060589 −55.9 2 carb. acid x x 492.0 132.9 4.8 7 ± 3 >50 >50
2 BAS00631909 −51.6 14 nitro x x 515.4 102.8 5.6 3 ± 1 20.5 ± 4.4 16.7 ± 2.2
3 BAS00590245 −51.4 16 carbonyl x 514.3 64.1 4.7 45 ± 16 18.6 ± 2.5 25.9 ± 1.0
4 BAS00380830 −50.9 21 nitro x 438.5 108.9 5.0 71 ± 28 4.0 ± 0.1 4.5 ± 0.2
5 BAS00434932 −49.5 29 nitro x 385.5 61.5 4.2 27 ± 6 >50 >50
6 BAS01060577 −49.2 33 nitro x x 449.9 134.2 3.7 32 ± 7 49.2 ± 1.2 >50
7 BAS01123443 −54.2 5 carb. acid x x 463.9 134.8 3.9 48 ± 18 >50 >50
Hit expansion of compound 4
4a BAS02102259 −50.8  2l nitro x 506.6 127.1 5.6 >100 21.1 ± 1.5 43.3 ± 9.5
4b BAS00619651 −50.7 3 nitro x 486.6 112.6 6.0 88 ± 57 >50 >50
4c BAS01404025 −49.8 6 nitro x 502.6 121.6 5.7 49 ± 21 >50 >50
4d BAS02102292 −49.4 7 nitro x 520.6 126.8 5.7 23 ± 12 >50 >50
4e BAS02102245 −49.4 8 nitro x 520.6 124.8 5.7 46 ± 14 >50 >50
4f BAS01547732 −48.9 13 nitro x 492.5 130.1 5.1 76 ± 39 19.4 ± 1.9 21.1 ± 1.2
4g BAS00111586 −48.8 15 nitro x 446.5 111.2 5.0 60 ± 37 6.5 ± 1.0 5.6 ± 0.5
4h BAS00916022 −48.0 20 nitro x 508.6 114.0 6.4 >100 >50 >50
4i BAS00381203 −47.2 24 nitro x 398.5 110.2 4.3 >100 23.4 ± 5.5 21.4 ± 0.3
apredicted free energy of binding of the ligand (kcal/mol) according to BeAR (MM-pBSA). bRanking position according to BeAR (MM-pBSA). cClassification of the 
ligand depending on the chemical group interacting with the conserved catalytic Lys33. doccupation of the inner (ANS1) and outer (ANS2) pocket. eMolecular 
weight (range 95% of drugs 130/725). fpolar surface area (range 95% of drugs 7/200 Ǻ2). gLog of the octanol/water partition coefficient  (range 95% of drugs 
-2/6.5). heC50 values (μM) determined from binding competition with ANS, with standard deviation. 
iIC50 values (μM) obtained in cell-based assays performed 
with MDA-MB231 and ZR-75–1 breast cancer cell lines, with standard deviation. lRanking position within the focused library of 2217 analogs of compound 4.
Figure  1. Concentration-dependent displacement of ANS from CDK2. 
panel (A) reports the displacement activity of compounds 1–7, while (B) 
shows the activity of six (4b–4g) of the nine compounds derived from 
the hit expansion of compound 4. Compounds 4a, 4h, and 4i did not 
show appreciable displacement activity.
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1–7 and ANS is not surprising, considering that this assay 
makes use of pre-formed CDK2/Cyclin A complexes in which 
the kinase is in the active conformation. In the CDK2/Cyclin 
A active conformation the ANS allosteric site is inevitably closed 
and therefore not accessible to ligands. This is demonstrated by 
the comparison of plenty of crystal structures of CDK2 in the 
active (CDK2/Cyclin A or E complexes) vs. inactive (CDK2) 
conformations available in the Protein Data Bank. As a matter 
of fact, detection of allosteric ligands using standard kinase 
activity assays is known to be challenging, as these methods 
preferentially detect compounds that bind to active kinases in 
an ATP-competitive manner.22,23 Nevertheless, a 30% inhibition 
of kinase activity was achieved when a 100 μM concentration of 
compound 4 was pre-incubated with CDK2 before the addition 
of Cyclin A and the substrate Rb, confirming the ability of this 
compound to bind and partially inhibit CDK2 activity when 
pre-formed CDK2/Cyclin A complexes are not used (data not 
shown). Considering the tight binding of Cyclin A for CDK2, it 
is conceivable that more potent analogs of compounds 1–7 may 
inhibit complex formation with cyclins more effectively.
The 7 compounds were then tested for their ability to inhibit 
the growth of human breast cancer cells in vitro, using 2 different 
human breast cancer cell lines, MDA-MB231 and ZR-75–1. As 
reported in Table 1, the most effective compound was 4, with a 
concentration able to inhibit the growth by 50% (IC
50
) of 4 and 
4.5 μM for MDA-MB231 and ZR-75–1, respectively. Four of the 
7 compounds (1, 5–7) did not show appreciable activity (IC
50
> 50 
μM). Compounds 2 and 3 showed IC
50
 values around 20 μM. 
Compounds 1 and 2 were the most effective in displacing ANS 
from CDK2, but only 2 showed appreciable activity in cell-based 
assays. Moreover, compound 4 was the less efficient in binding 
CDK2 but the most active in the cell-based assays. These findings 
indicate the lack of a clear correlation between in vitro CDK2 
binding characteristics of these compounds and their effect on 
cells, a commonly observed phenomenon generally arising from 
differential cell membrane permeability of compounds.24,25 
Nevertheless, compound 4 was able to effectively inhibit CDK2-
mediated phosphorylation of Retinoblastoma at a concentration 
of 4 μM (its IC
50
 in cells). In fact, Figure 2 shows that treatment 
of MDA-MB231 cells with the specific CDK2 inhibitor SU9516 
(10 μM) or compound 4 resulted, after 24 h, in a clear reduction 
of T821-Rb phosphorylation, a CDK2 preferred site,26 without 
affecting the phosphorylation of a CDK4/CDK6 preferred site 
(S780-Rb). These data demonstrate that compound 4 inhibits 
CDK2 activity in cells at concentrations inhibiting cell growth 
and provide proof of principle that its mechanism of action is fully 
compatible with a selective inhibition of CDK2 phosphorylation.
The predicted binding modes of the 7 active hits were confirmed 
by performing a more exhaustive sampling and clustering of 
docked orientations compared with the original conditions 
applied for virtual screening. The results are collectively reported 
in Tables S1 and S2, and the overall best-scoring solutions 
according to BEAR/MM-PBSA chosen as representative binding 
modes of each compound are graphically shown in Figure 3. 
Compounds 1 and 7 are predicted to bind the inner catalytic 
Lys33 with the 6-carboxylate group and the outer Lys56 group 
with the 2-nitro group of the 2-nitro-phenylsulfanyl moiety. The 
remaining interactions were mainly hydrophobic contacts with 
Tyr15, Ile35, Ile52, Leu55, Val69, Leu76, Leu78, and Phe80. 
Compounds 2 and 6 bind Lys33 with the nitro group of the 
2-nitro-phenylsulfanyl moiety, and Lys56 and His71 with the 
carboxylate group. Being characterized by 2 polar heads separated 
by a hydrophobic core, head-to-tail orientations of compounds 
1/7vs.2/6 having each polar group interacting once with Lys33 
and once with Lys56 are reasonable. Other interactions are mainly 
hydrophobic. Compound 3 binds Lys33 with the pyrimidin-4-one 
carbonyl and interacts favorably with Tyr15, Ile35, Leu55, Leu66, 
Leu78, Phe80, Leu148, Val154, and Val156. The nitro group of 
compound 4 interacts with Lys33, and the carbonyl group of the 
cyclohex-2-enone ring hydrogen bonds with the Tyr15 hydroxyl. 
The nitrophenyl ring establishes stacking interactions with Tyr15, 
while the rest of the molecule is in contact with Ile35, Ile52, 
Leu55, Val64, Leu66, Leu78, Val154, and Val156. Compound 
5 binds Lys33 with the nitro group, while the remainder of the 
molecule interacts with Tyr15, Ile35, Ile52, Leu55, Ile63, Val64, 
Leu66, Phe80, Phe146, Leu148, Val154, and Val156.
Hit expansion of compound 4
With the aim of potentially identifying additional biologically 
active hits and to provide a first exploration of their SAR, 
commercially available analogs of compound 4, i.e., the compound 
showing the most interesting activity in cancer cell-based assays, 
were searched for in the Asinex database. To this end, a focused 
library of commercial analogs of 4 was prepared by including 
compounds with a similarity Tanimoto coefficient (Tc) of at least 
0.7 with this reference compound. This operation resulted in 2217 
compounds, 1536 of which were not post-processed with BEAR 
in the primary virtual screening owing to the AutoDock energy 
score cut-off of −11 kcal/mol imposed when selecting molecules for 
post-docking refinement and rescoring. The entire focused library 
(2217 compounds) was then submitted to post-docking using the 
same procedure described for the primary screening. According 
to MM-PBSA, compound 4 ranked first in this focused library, 
but a number of analogs with interesting scores emerged, some of 
which were not processed before because their AutoDock scores 
were less favorable than the cut-off value. Nine analog compounds 
(compounds 4a–4i, included in Chart 1) with favorable 
MM-PBSA scores and binding modes consistent with that of the 
Figure 2. Inhibition of Rb phosphorylation by compound 4 and SU9516 
in MDA-MB231 cells. proteins were separated on SDS page, electroblot-
ted to nitrocellulose, and hybridized with antibodies against phoshory-
lated Rb (t821, left panel and S780, right panel). Blots were subsequently 
hybridized with antibodies against total Rb and actin (used as loading 
control). C, control, untreated cells; SU, cells treated with SU9516 (10 μM); 
4, cells treated with compound 4 (4 μM).
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parent compound 4 were finally selected for biological evaluation. 
Their chemical and biological properties are included in Table1.
Three compounds (4a, 4h, 4i) did not show appreciable ANS 
displacement activity (Table 1). The remaining 6 analogs had 
EC
50
 values ranging from 23 to 88 μM. In some cases, e.g., 
compound 4d, the affinity for CDK2 was slightly improved with 
respect to that of the parent compound 4. The dose-response 
curves of the 6 active analogs obtained from 3 independent 
experiments are shown in Figure 1B. Moreover, the compounds 
showing appreciable ANS displacement activity were also tested 
in the presence of staurosporine to confirm that they bind in the 
allosteric ANS pocket. Again, the displacement ability of the 6 
tested compounds did not change in the presence of staurosporine 
(Fig. S2), confirming their allosteric binding.
When tested in cell based assays on both MDA-MB231 and 
ZR-75–1 human breast cancer cell lines, compound 4g showed 
IC
50
 values similar to those of compound 4, while compounds 
4a, 4f, and 4i had IC
50
 values around 20 μM. The remaining 
5 compounds did not show appreciable antiproliferative activity 
(Table 1).
Conclusions
The recent availability of the first crystal structure of a member 
of the CDK family with an open allosteric pocket in proximity 
of αC helix allowed us to apply a virtual screening protocol that 
led to the successful identification of the first-in-class allosteric 
inhibitors of CDK2. Using a combination of high-throughput 
docking and refinement and rescoring performed with our post-
docking tool BEAR, we rationally selected and tested 35 top-
ranked compounds and finally identified 7 ligands able to bind 
CDK2 in the allosteric ANS pocket, corresponding to a hit rate 
of 20%.
The active ligands were able to displace ANS from CDK2 at 
micromolar concentrations. The ligands competed with ANS for 
the allosteric pocket previously demonstrated by crystallography 
Figure 3. predicted binding modes of compounds 1–7 in the allosteric pocket of CDK2, highlighting (left) the location of each compound in the overall 
fold, (right) the close up of the allosteric site with selected residues interacting with the ligands. For comparative purposes, the first box shows the bind-
ing mode of the 2 ANS molecules present in the crystal structure of the binary complex (pDB code 1pXF).
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of the CDK2–ANS complex,15 thus showing a mechanism fully 
compatible with the expected allosteric binding. Competition 
experiments repeated in the presence of the ATP-competitive 
inhibitor staurosporine confirmed the truly allosteric nature of 
these ligands. All tested compounds did not show appreciable 
direct inhibition of CDK2/Cyclin A kinase activity at the 
concentrations used in our experiments. In fact, when the assay 
makes use of pre-formed CDK2/Cyclin A complexes, the kinase 
is in the active conformation and the CDK2 allosteric site is 
inevitably closed and therefore not accessible to allosteric ligands. 
On the contrary, a 30% inhibition of kinase activity was observed 
when a 100 μM concentration of compound 4 was pre-incubated 
with CDK2 before the addition of Cyclin A and the substrate Rb, 
confirming the ability of this compound to bind and partially 
inhibit CDK2 activity when pre-formed active CDK2/Cyclin A 
complexes are not used. It is not excluded that stronger allosteric 
binders would achieve more effective competition with Cyclin A 
and consequently show up higher direct inhibition by shifting the 
equilibrium toward the inactive conformation. This possibility 
will be explored when tighter allosteric binders will be available. 
Therefore, future efforts will be directed toward hit optimization 
and generation of more potent analogs.
Importantly, some of these ligands inhibited the proliferation 
of MDA-MB231 and ZR-75-1 breast cancer cells with IC
50
 
values in the low micromolar range. In particular, compounds 
4 and 2 had IC
50
 values of 4 μM and 20 μM, respectively. 
Remarkably, treatment of MDA-MB231 cells with the most 
potent compound 4 resulted in a clear reduction of a CDK2 
preferred phosphorylation site (T821-Rb) but not of a CDK4/6 
preferred site (S780-Rb). This finding indicates that 4 is able 
to selectively inhibit CDK2-mediated Rb phosphorylation and 
confirms that its mechanism of action is fully compatible with a 
selective inhibition of CDK2 phosporylation in cells. In cells, the 
amount of CDK2 complexed with Cyclin A changes in response 
to varying Cyclin A levels, and CDK2 is not always complexed 
with Cyclin.27–29 Therefore, in cells, uncomplexed CDK2 in the 
inactive conformation can effectively bind allosteric inhibitors, 
and this, in turn, would reduce its binding with Cyclin A.
Finally, hit expansion of compound 4 provided an additional 
ligand 4g with similar in vitro potency. No clear correlation 
between in vitro CDK2 binding and antiproliferative activity in 
cells was observed, as commonly reported in the literature because 
of differential cell membrane permeability of compounds.24,25 
Indeed, several factors can influence the antiproliferative activity of 
a compound including its stability, its intracellular accumulation, 
and metabolism. Therefore, further optimization of drug potency, 
cellular penetration, and SAR investigations on the newly identified 
hits will be required to further develop these compounds.
Materials and Methods
Compound database
The Asinex collection of commercially-available compounds 
was downloaded in Mol2 format from the ZINC database 
(“Usual” subset) (July 2011).30 This data set contained a total 
of 600 722 compounds including protonation variants and 
tautomers at pH values from 5.75 to 8.25, corresponding to 
545 609 unique ZINC IDs.
Protein preparation
The crystallographic coordinates of CDK2 in complex with 
2 molecules of 8-anilino-1-naphtalene sulfonate (ANS) used for 
docking were taken from the Protein Data Bank (PDB), PDB 
code 3PXF.15 The 2 ANS and all water molecules were removed 
from the structure. Hydrogen atoms were added to the protein 
structure using the Leap module of Amber10.31 All Asp and 
Glu were negatively charged and all Lys and Arg were positively 
charged. This structure was used as starting point in both 
docking and post-docking calculations.
Docking
Docking calculations were performed with AutoDock 
4.2.3.17 The protein structure was converted into pdbqt file by 
merging non-polar hydrogen atoms to heavy atoms and assigning 
Gasteiger partial charges and atom types with MGLTools 1.5.4.32 
For docking, each molecule in the Asinex database was assigned 
Gasteiger partial charges with MGLTools 1.5.3. On the contrary, 
the original CM2 charges present in ZINC were retained for the 
post-docking analyses made with BEAR (see below). AutoGrid 
was employed to build grid maps around the allosteric site of 
CDK2, with a spacing of 0.375 Å and centered on the center 
of mass of the 2 ANS molecules. Grid dimensions were set so as 
to include the 2 ANS molecules and a number of buried water 
molecules around them (W318, 327, 338, 374, 406, 473, 478, 
496 in 3PXF) that could be displaced by the docked compounds. 
The number of resulting grid points were 62 × 46 × 44 (0.375 
Å spacing). The Lamarckian genetic algorithm was used for 
the conformational sampling. For each compound, 10 runs 
were performed with a population size of 150, 250 000 energy 
evaluations, and 27 000 maximum generations. Clustering was 
performed with a cluster tolerance of 2 Å. Re-docking of ANS 
with these parameters retrieved a binding mode that was almost 
identical with that of the co-crystallized ligand (RMSD of 0.529 
Å). Of the 2 ANS molecules bound to the crystal, AutoDock 
placed the ligand in the inner (residue 305.A in 3PXF) and 
conceivably more favorable binding site, with a score of −7.4 kcal/
mol.
The Asinex database was ranked according to the lowest-
energy scoring docking solution.
Post-docking with BEAR
The best scoring docking complexes obtained with AutoDock 
were post-processed with BEAR (Binding Estimation After 
Refinement), our in-house structural refinement and rescoring 
tool based on molecular dynamics and MM-PBSA.18–21 Post-
docking was performed on the top fraction of the ranked 
database obtained by applying an AutoDock energy score 
cut-off of −11 kcal/mol (~27 000 compounds, corresponding 
to ~5% of the initially docked database). The best AutoDock 
score was −15.6 kcal/mol. Each complex was submitted to the 
BEAR refinement and rescoring procedure using the Amber 
force field ff0333 for the protein and the General Amber force 
field (gaff)34 for small molecules. CM2 partial atomic charges 
were used for small molecules. The protocol consists of 3 steps 
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based on molecular mechanics (MM) and dynamics (MD) 
cycles. In particular, 2000 steps of MM energy minimization of 
the whole protein–ligand complex were performed, followed by 
100 ps MD where the ligand was allowed to move, and a final 
re-minimization of the entire complex. A distance-dependent 
dielectric constant ε = 4r and a non-bonded cut-off of 12 Å were 
used. At the end, the binding free energy of each compound in 
the refined complex was computed by using the MM–PBSA 
method.35 The Poisson–Boltzmann algorithm was used to solve 
the polar term of the solvation free energy, while the LCPO 
method was applied to calculate the solvent-accessible surface 
area for the non-polar contribution. Dielectric constants of 80 
and 1 were used for solvent and solute, respectively. BEAR has 
been extensively validated and used in VS. Other details can be 
found in references 18–21.
Post-docking results were ranked according to the MM-PBSA 
binding free energy scores, and top ranked compounds were 
visually inspected with Chimera 1.6.2.36 Before selection, the 
top 100 compounds were clustered into chemical classes using 
the Canvas similarity and clustering utility available in Maestro 
9.2,37 using default settings. Thirty-five compounds were finally 
selected, purchased, and submitted to biological evaluations.
Binding mode predictions of the 7 active hits
The binding modes of the active compounds 1–7 discovered 
by virtual screening were confirmed by performing a more 
exhaustive sampling and clustering of docked orientations 
compared with the original conditions applied for virtual 
screening (100 runs of Lamarckian genetic algorithm instead 
of 10). Since the ZINC database did not contain all possible 
stereoisomers of compounds 1–7, complete sets of stereoisomers 
were re-generated using the LigPrep utility available in Maestro 
(Schrödinger 2011 suite). For each enantiomer, 100 docking runs 
were performed with AutoDock, and the resulting orientations 
were clustered using a default RMS tolerance of 2 Å. For each 
enantiomer, clusters of orientations were ranked according to 
(1) the lowest energy score predicted by AutoDock and (2) the 
population of each cluster, i.e., the number of orientations that 
populated each cluster. Then, representative orientations of the 
5 best-scoring clusters and of the 5 most-populated clusters were 
post-processed with BEAR. CM2 atomic charges present in the 
ZINC database were used for post-docking refinement. The 
docking energy (AD4) and MM-PBSA (BEAR) scores obtained 
for each post-processed orientation are reported in Tables S1 
and S2 as supplementary information. Finally, the overall best-
scoring solutions according to MM-PBSA (BEAR) were chosen 
as representatives of the binding mode of each compound.
Hit expansion of compound 4
With the aims of exploring the SAR of the identified hits and 
potentially discovering other biologically active hits, commercially 
available analogs of compound 4, i.e., the compound showing 
the most interesting activity in cancer cell-based assays, were 
searched in the Asinex database and then processed with the 
same docking and post-docking procedure described above. To 
prepare the focused library, compound 4 was taken as a reference 
for similarity searching calculations. Molecular ACCess System 
(MACCS) fingerprints38 as implemented in OpenBabel 2.3.139 
were computed for the reference compound 4 and for the complete 
Asinex database. Then, similarity searching calculations made 
with OpenBabel were ranked according to Tanimoto coefficient 
(Tc) values computed for each database molecule vs. the reference 
compound 4, and compounds with a Tc value of at least 0.7 were 
selected. This selection led to a focused library of 1108 unique 
compounds, which corresponded to 2217 database entries by 
including multiple tautomers and protonation states. Of these, 
681 were already processed in the primary virtual screening, 
while the remaining 1536 had been excluded owing to the 
AutoDock energy score cut-off of −11 kcal/mol imposed when 
selecting molecules for post-docking refinement and rescoring. 
The 2217 compounds were then submitted to docking and post-
docking calculations using the same procedure described for the 
primary screening.
ADME predictions
ADME properties of the tested compounds were evaluated by 
using QikProp v.3.4 (Schrödinger suite).40
Biological assays
Recombinant CDK2 was purified from E. coli using a GST-
CDK2 fusion construct. E. coli transformed with a GST–CDK2 
plasmid were grown overnight in LB medium in selection 
antibiotic. Bacterial culture was then diluted 1:100 and grown 
at 37 °C until reached an absorbance value of 0.6 at 600 nM. At 
this point temperature was set down to 30 °C and induction with 
0.5 mM IPTG (isopropyl-b-D-thiogalactoside) was performed 
for additional 6 h. Bacterial culture was centrifuged at 4000 rpm 
for 20 min and pellet resuspended in PBS. Bacterial cells were 
sonicated 5 times for 20 s and incubated in the presence of 1% 
triton X100 for 30 min at 4 °C. After centrifugation at 12 000 
rpm for 10 min at 4 °C, GST beads were added to the supernatant 
and incubated for further 60 min at 4 °C. Lysates were washed 
3 times in PBS and GST-CDK2 eluted with reduced GSH (10 
mM in 50 mM Tris pH 8). The purity of the protein was checked 
by SDS-PAGE electrophoresis and the amount determined using 
the Protean assay (BIORAD).
ANS displacement assay was performed as described by 
Martin et al.16 The assays were performed in 96-well plates in 
a total volume of 50 microliters of 40 mM Hepes pH 7.5 ANS 
(final concentration 50 μM), and different concentrations of the 
different compounds (ranging from 0.01 to 50 μM) were added 
and the fluorescence (excitation 360 nM, emission 460 nM) 
measured using an Infinite M200 Microplate Reader (Tecan) 
to determine the intrinsic fluorescence of the compounds. 
Recombinant CDK2 (final concentrations 1.5 μM) was then 
added and a second measurement taken. Using the formula 
reported in reference 16 the relative displacement for each 
compound was determined.
To discriminate between type I/II and type III ligands, 
competition assays in the presence of Staurosporine (2.5 μM) 
were performed as described in reference 16.
The inhibition of CDK2/Cyclin A kinase activity was 
determined using a commercially available luminescent-based 
method (ADP-Glo™ Kinase Assay, Promega) determining the 
ability of recombinant CDK2/Cycin A complex to phosphorylate 
one of its major substrate, Rb. The assay was performed 
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following the manufacturer’s instructions. Staurosporine was 
used as positive control. Luminescence was determined with a 
plate-reading luminometer (Promega). In some experiments 
compound 4 at a 100 μM concentration was pre-incubated for 
30 min with CDK2 alone, before the addition of cyclin A and 
the substrate Rb.
Cell growth-inhibitory activity was determined using the 
MTS test. MDA-MB231 and ZR75–1 breast cancer cells were 
used for these experiments. Cells were seeded in 96-well plates 
at 35 000 cells/ml/well. Forty-eight hours after cell seeding 
different concentrations of the compounds were added, and the 
plates incubated at 37 °C for additional 72 h. At the end of the 
treatment period, MTS reagent (Promega) was added to each 
well, and the plates were incubated at 37 °C for 4 h in 5% CO
2
. 
Cell proliferation was evaluated by measuring the absorbance at 
490 nm using an infinite M200 Microplate Reader (Tecan). A 
nonlinear regression method was used to calculate IC
50
 values 
(concentrations required to produce 50% growth inhibition).
Phosphorylation of CDK2 substrate Rb in cells was 
determined by western blotting. Cells were treated with 
compound 4, and after 24 h lysed in ice-cold buffer containing 
50 mM TRIS-HCl pH 7.4, 250 mM NaCl, 0.1% Nonidet NP40, 
5 mM EDTA and NaF 50 mM with a protease inhibitor cocktail 
(Sigma). Lysates were cleared by centrifuging at 13 000 rpm 
for 5 min. To detect phosphorylated Rb, 30 µg of total protein 
extracts were loaded on 8% SDS-PAGE and then transferred 
to a nitrocellulose membrane. The polyclonal anti-phospho-Rb 
T821 was from Invitrogen, the polyclonal anti-phospho-Rb 
S780 was from Cell Signaling, while anti-total Rb and anti-actin 
were from Santa Cruz Biotechnology. Bands were visualized by 
chemioluminescence (ECL, Amersham).
The tested compounds were purchased from Asinex.41 Vendor 
codes of the 35 purchased compounds are: BAS04379720; 
BAS04379667; BAS03379043; BAS03302486; BAS01840948; 
BAS01355752; BAS01213474; BAS01118120; BAS01060589; 
BAS01060577; BAS01052182; BAS01052061; BAS00732157; 
BAS00631909; BAS00619651; BAS00608642; BAS00590245; 
BAS00448634; BAS00434932; BAS00410884; BAS00410708; 
BAS00398159; BAS00380830; BAS00319966; BAS00261429; 
ASN24804207; ASN10813896; ASN07272942; ASN06130191; 
ASN06123095; ASN05298123; ASN05258995; ASN05115618; 
ASN04503530; BAS01123443. The vendor codes of the 
nine analogs of compound 4 purchased for hit expansion are: 
BAS00111586; BAS00381203; BAS01404025; BAS01547732; 
BAS02102292; BAS00619651; BAS00916022; BAS02102245; 
BAS02102259.
The vendor had verified compound purity by liquid 
chromatography-mass spectrometry (LC-MS) or nuclear 
magnetic resonance (NMR) experiments. All compounds had 
at least 95% purity except 1 (92%) and 3 (93%). All chiral 
compounds were purchased and tested as racemic mixtures.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Acknowledgments
Financial support from the Nando Peretti Foundation (grant 
NPF 2013–25) is gratefully acknowledged. Computational 
resources were provided by the ISCRA (Italian Super Computing 
Resource Allocation) grant “BEAR” Class A # HP10A6E2CI. 
We wish to thank Fabiana Caporuscio for critical reading of the 
manuscript.
Supplemental Materials
Supplemental materials may be found here:
www.landesbioscience.com/journals/cc/article/29295
References
1. Zhang J, Yang PL, Gray NS. Targeting cancer with 
small molecule kinase inhibitors. Nat Rev Cancer 
2009; 9:28-39; PMID:19104514; http://dx.doi.
org/10.1038/nrc2559
2. Eglen R, Reisine T. Drug discovery and the human 
kinome: recent trends. Pharmacol Ther 2011; 
130:144-56; PMID:21256157; http://dx.doi.
org/10.1016/j.pharmthera.2011.01.007
3. Palmieri L, Rastelli G. αC Helix Displacement as 
a General Approach for Protein Kinases Allosteric 
Modulation. Drug Discov Today 2013; 18:407-
14; PMID:23195331; http://dx.doi.org/10.1016/j.
drudis.2012.11.009
4. Rabiller M, Getlik M, Klüter S, Richters A, 
Tückmantel S, Simard JR, Rauh D. Proteus in the 
world of proteins: conformational changes in protein 
kinases. Arch Pharm (Weinheim) 2010; 343:193-
206; PMID:20336692; http://dx.doi.org/10.1002/
ardp.201000028
5. Lamba V, Ghosh I. New directions in target-
ing protein kinases: focusing upon true allosteric 
and bivalent inhibitors. Curr Pharm Des 2012; 
18:2936-45; PMID:22571662; http://dx.doi.
org/10.2174/138161212800672813
6. Fang Z, Grütter C, Rauh D. Strategies for the selec-
tive regulation of kinases with allosteric modulators: 
exploiting exclusive structural features. ACS Chem 
Biol 2013; 8:58-70; PMID:23249378; http://dx.doi.
org/10.1021/cb300663j
7. Lapenna S, Giordano A. Cell cycle kinases as thera-
peutic targets for cancer. Nat Rev Drug Discov 
2009; 8:547-66; PMID:19568282; http://dx.doi.
org/10.1038/nrd2907
8. CDK Inhibitor Triples PFS in Breast Cancer. Cancer 
Discov 2013; 3:4
9. Russo AA, Jeffrey PD, Patten AK, Massagué J, 
Pavletich NP. Crystal structure of the p27Kip1 
cyclin-dependent-kinase inhibitor bound to 
the cyclin A-Cdk2 complex. Nature 1996; 
382:325-31; PMID:8684460; http://dx.doi.
org/10.1038/382325a0
10. McInnes C, Andrews MJ, Zheleva DI, Lane DP, 
Fischer PM. Peptidomimetic design of CDK inhibi-
tors targeting the recruitment site of the cyclin 
subunit. Curr Med Chem Anticancer Agents 
2003; 3:57-69; PMID:12678915; http://dx.doi.
org/10.2174/1568011033353506
11. Andrews MJ, McInnes C, Kontopidis G, Innes L, 
Cowan A, Plater A, Fischer PM. Design, synthesis, 
biological activity and structural analysis of cyclic 
peptide inhibitors targeting the substrate recruit-
ment site of cyclin-dependent kinase complexes. Org 
Biomol Chem 2004; 2:2735-41; PMID:15455144; 
http://dx.doi.org/10.1039/b409157d
12. Corsino P, Horenstein N, Ostrov D, Rowe T, Law M, 
Barrett A, Aslanidi G, Cress WD, Law B. A novel class 
of cyclin-dependent kinase inhibitors identified by 
molecular docking act through a unique mechanism. 
J Biol Chem 2009; 284:29945-55; PMID:19710018; 
http://dx.doi.org/10.1074/jbc.M109.055251
13. Ortega S, Malumbres M, Barbacid M. Cyclin 
D-dependent kinases, INK4 inhibitors and can-
cer. Biochim Biophys Acta 2002; 1602:73-87; 
PMID:11960696
14. Echalier A, Endicott JA, Noble ME. Recent devel-
opments in cyclin-dependent kinase biochemi-
cal and structural studies. Biochim Biophys Acta 
2010; 1804:511-9; PMID:19822225; http://dx.doi.
org/10.1016/j.bbapap.2009.10.002
15. Betzi S, Alam R, Martin M, Lubbers DJ, Han H, 
Jakkaraj SR, Georg GI, Schönbrunn E. Discovery of 
a potential allosteric ligand binding site in CDK2. 
ACS Chem Biol 2011; 6:492-501; PMID:21291269; 
http://dx.doi.org/10.1021/cb100410m
16. Martin MP, Alam R, Betzi S, Ingles DJ, Zhu J-Y, 
Schönbrunn E. A novel approach to the discovery 
of small-molecule ligands of CDK2. Chembiochem 
2012; 13:2128-36; PMID:22893598; http://dx.doi.
org/10.1002/cbic.201200316
17. Morris GM, Huey R, Lindstrom W, Sanner MF, 
Belew RK, Goodsell DS, Olson AJ. AutoDock4 and 
AutoDockTools4: Automated docking with selective 
receptor f lexibility. J Comput Chem 2009; 30:2785-
91; PMID:19399780; http://dx.doi.org/10.1002/
jcc.21256
18. Rastelli G, Del Rio A, Degliesposti G, Sgobba M. 
Fast and accurate predictions of binding free energies 
using MM-PBSA and MM-GBSA. J Comput Chem 
2010; 31:797-810; PMID:19569205
©
20
14
 L
an
de
s 
B
io
sc
ie
nc
e.
 D
o 
no
t d
is
tri
bu
te
.
www.landesbioscience.com Cell Cycle 2305
19. Degliesposti G, Portioli C, Parenti MD, Rastelli 
G. BEAR, a novel virtual screening methodol-
ogy for drug discovery. J Biomol Screen 2011; 
16:129-33; PMID:21084717; http://dx.doi.
org/10.1177/1087057110388276
20. Sgobba M, Caporuscio F, Anighoro A, Portioli C, 
Rastelli G. Application of a post-docking procedure 
based on MM-PBSA and MM-GBSA on single and 
multiple protein conformations. Eur J Med Chem 
2012; 58:431-40; PMID:23153814; http://dx.doi.
org/10.1016/j.ejmech.2012.10.024
21. Degliesposti G, Kasam V, Da Costa A, Kang HK, 
Kim N, Kim DW, Breton V, Kim D, Rastelli G. 
Design and discovery of plasmepsin II inhibitors 
using an automated workflow on large-scale grids. 
ChemMedChem 2009; 4:1164-73; PMID:19437467; 
http://dx.doi.org/10.1002/cmdc.200900111
22. Lebakken CS, Reichling LJ, Ellefson JM, Riddle 
SM. Detection of allosteric kinase inhibitors by 
displacement of active site probes. J Biomol Screen 
2012; 17:813-21; PMID:22453235; http://dx.doi.
org/10.1177/1087057112439889
23. Simard JR, Getlik M, Grütter C, Schneider R, Wulfert 
S, Rauh D. Fluorophore labeling of the glycine-rich 
loop as a method of identifying inhibitors that bind to 
active and inactive kinase conformations. J Am Chem 
Soc 2010; 132:4152-60; PMID:20201574; http://
dx.doi.org/10.1021/ja908083e
24. Gleeson MP, Hersey A, Montanari D, Overington J. 
Probing the links between in vitro potency, ADMET 
and physicochemical parameters. Nat Rev Drug 
Discov 2011; 10:197-208; PMID:21358739; http://
dx.doi.org/10.1038/nrd3367
25. Rastelli G. Emerging topics in structure-based 
virtual screening. Pharm Res 2013; 30:1458-63; 
PMID:23468050; http://dx.doi.org/10.1007/
s11095-013-1012-9
26. Schmitz NM, Leibundgut K, Hirt A. CDK2 catalytic 
activity and loss of nuclear tethering of retinoblas-
toma protein in childhood acute lymphoblastic leu-
kemia. Leukemia 2005; 19:1783-7; PMID:16107892; 
http://dx.doi.org/10.1038/sj.leu.2403900
27. Morgan DO. Principles of CDK regulation. Nature 
1995; 374:131-4; PMID:7877684; http://dx.doi.
org/10.1038/374131a0
28. Vermeulen K, Van Bockstaele DR, Berneman ZN. 
The cell cycle: a review of regulation, deregula-
tion and therapeutic targets in cancer. Cell Prolif 
2003; 36:131-49; PMID:12814430; http://dx.doi.
org/10.1046/j.1365-2184.2003.00266.x
29. Arellano M, Moreno S. Regulation of CDK/cyclin 
complexes during the cell cycle. Int J Biochem Cell 
Biol 1997; 29:559-73; PMID:9363633; http://
dx.doi.org/10.1016/S1357-2725(96)00178-1
30. Irwin JJ, Sterling T, Mysinger MM, Bolstad ES, 
Coleman RG. ZINC: a free tool to discover chem-
istry for biology. J Chem Inf Model 2012; 52:1757-
68; PMID:22587354; http://dx.doi.org/10.1021/
ci3001277
31. Case DA, Darden TE, Cheatham TE III, Simmerling 
CL, Wang J, Duke RE, Luo R, Crowley M, Walker 
RC, Zhang W, et al. (2008), AMBER 10, University 
of California, San Francisco
32. Sanner MF. Python: a programming language for 
software integration and development. J Mol Graph 
Model 1999; 17:57-61; PMID:10660911
33. Duan Y, Wu C, Chowdhury S, Lee MC, Xiong G, 
Zhang W, Yang R, Cieplak P, Luo R, Lee T, et al. 
A point-charge force field for molecular mechanics 
simulations of proteins based on condensed-phase 
quantum mechanical calculations. J Comput Chem 
2003; 24:1999-2012; PMID:14531054; http://
dx.doi.org/10.1002/jcc.10349
34. Wang J, Wolf RM, Caldwell JW, Kollman PA, 
Case DA. Development and testing of a general 
amber force field. J Comput Chem 2004; 25:1157-
74; PMID:15116359; http://dx.doi.org/10.1002/
jcc.20035
35. Kollman PA, Massova I, Reyes C, Kuhn B, Huo S, 
Chong L, Lee M, Lee T, Duan Y, Wang W, et al. 
Calculating structures and free energies of complex 
molecules: combining molecular mechanics and 
continuum models. Acc Chem Res 2000; 33:889-
97; PMID:11123888; http://dx.doi.org/10.1021/
ar000033j
36. Pettersen EF, Goddard TD, Huang CC, Couch 
GS, Greenblatt DM, Meng EC, Ferrin TE. UCSF 
Chimera–a visualization system for exploratory 
research and analysis. J Comput Chem 2004; 
25:1605-12; PMID:15264254; http://dx.doi.
org/10.1002/jcc.20084
37. Suite 2011: Maestro, version 9.2, Schrödinger, LLC, 
New York, NY, 2011
38. RDKit: Cheminformatics and Machine Learning 
Software. http://www.rdkit.org/
39. O’Boyle NM, Banck M, James CA, Morley C, 
Vandermeersch T, Hutchison GR. Open Babel: 
An open chemical toolbox. J Cheminform 
2011; 3:33; PMID:21982300; http://dx.doi.
org/10.1186/1758-2946-3-33
40. Suite 2011: QikProp, version 3.4, Schrödinger, LLC, 
New York, NY, 2011
41. Asinex; Asinex Ltd: Moscow; http://www.asinex.com
